Ivonescimab Improves Quality of Life in First-Line NSCLC Patients without Chemotherapy The HARMONi-2 study reveals that Ivonescimab significantly enhances health-related quality of life for NSCLC patients without chemotherapy, outperforming Pembrolizumab.

Ivonescimab Improves Quality of Life in First-Line NSCLC Patients without Chemotherapy #China #Hong_Kong #Akeso #Ivonescimab #NSCLC

Akeso Reports Transformative Year with Remarkable Sales Growth in 2025 Akeso, Inc. reported its impressive 2025 annual financial results, showcasing notable growth and advancements in oncology and immunotherapy sectors.

Akeso Reports Transformative Year with Remarkable Sales Growth in 2025 #China #Hong_Kong #Akeso #Cadonilimab #Ivonescimab

U.S. Patient Overcomes Advanced Lung Cancer with New Immunotherapy in China A groundbreaking case highlights how a U.S. lung cancer patient found new hope through innovative immunotherapy at Jiahui International Cancer Center in Shanghai.

U.S. Patient Overcomes Advanced Lung Cancer with New Immunotherapy in China #China #Shanghai #Ivonescimab #Lung_Cancer #Jiahui_Cancer_Center

Akeso's Ivonescimab Earns Fifth Breakthrough Therapy Designation for Advanced Biliary Tract Cancer Treatment Akeso, Inc. has achieved a significant milestone with the fifth Breakthrough Therapy Designation for Ivonescimab, targeting advanced biliary tract cancer. This advancement underlines the drug's promising potential.

Akeso's Ivonescimab Earns Fifth Breakthrough Therapy Designation for Advanced Biliary Tract Cancer Treatment #China #Hong_Kong #Akeso #Ivonescimab #biliary_tract_cancer

Akeso's Ivonescimab Recognized Among Game-Changing Drugs for 2026 Akeso's innovative drug, ivonescimab, has been featured in FirstWord Pharma's list of pivotal medicines likely to shape the future of healthcare by 2026. Discover its potential impact.

Akeso's Ivonescimab Recognized Among Game-Changing Drugs for 2026 #China #Hong_Kong #pharmaceuticals #Akeso #Ivonescimab

Akeso Biopharma presenta la BLA de ivonescimab (anticuerpo biespecífico PD-1/VEGF) ante la FDA

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Oncología #CáncerDePulmón #NSCLC #CPNM #EGFR #PD1 #VEGF #AnticuerpoBiespecífico #Ivonescimab #SummitTherapeutics #FDA

Ivonescimab's Label Update in China: Positive Outcomes for Lung Cancer Patients Akeso, Inc. announces the approval of a significant label update for ivonescimab's dual benefits in progression-free and overall survival, aiding lung cancer patients.

Ivonescimab's Label Update in China: Positive Outcomes for Lung Cancer Patients #China #Hong_Kong #Akeso #Ivonescimab #HARMONi-A

Akeso Unveils Promising Phase II Efficacy Data for Ivonescimab in TNBC Treatment at ESMO IO 2025 Akeso, Inc. presented exciting Phase II clinical trial results for ivonescimab combined with chemotherapy as a first-line treatment for TNBC at ESMO IO 2025.

Akeso Unveils Promising Phase II Efficacy Data for Ivonescimab in TNBC Treatment at ESMO IO 2025 #Hong_Kong #TNBC #Akeso #Ivonescimab

Significant Advances in Cancer Treatment Reported with Ivonescimab at ESMO Asia 2025 Latest findings from the Phase III HARMONi-6 study showcase ivonescimab's potential to enhance quality of life for lung cancer patients, transforming treatment standards.

Significant Advances in Cancer Treatment Reported with Ivonescimab at ESMO Asia 2025 #Hong_Kong #Cancer_Treatment #Ivonescimab #HARMONi-6

Akeso's Breakthrough Drugs Secure Inclusion in China's NRDL, Enhancing Patient Treatment Options Akeso, Inc. announces the successful inclusion of five innovative drugs in China's National Reimbursement Drug List, improving treatment availability for patients.

Akeso's Breakthrough Drugs Secure Inclusion in China's NRDL, Enhancing Patient Treatment Options #China #Hong_Kong #Akeso #Ivonescimab #Ebronucimab

La NMPA de China aprueba la Ivonescimab Injection para su comercialización

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Ivonescimab #IvonescimabInjection #Yidafang #Akeso #AkesóBiofarmacéutica #NMPA #AprobaciónDeMedicamentos #Oncología #CáncerDePulmón #CPNM

Akeso Begins Phase I Trial for Personalized mRNA Vaccine Against Pancreatic Cancer Akeso, Inc. has initiated a Phase I clinical trial for its personalized mRNA vaccine, AK154, aimed at treating pancreatic cancer, both alone and with bispecific antibodies.

Akeso Begins Phase I Trial for Personalized mRNA Vaccine Against Pancreatic Cancer #Cadonilimab #Ivonescimab #AK154

Groundbreaking HARMONi-A Study Shows Ivonescimab's Effectiveness in NSCLC Treatment at SITC 2025 The recent presentation of the HARMONi-A study results highlights ivonescimab's significant potential in treating EGFR-mutated NSCLC, showcasing remarkable OS improvements.

Groundbreaking HARMONi-A Study Shows Ivonescimab's Effectiveness in NSCLC Treatment at SITC 2025 #China #Hong_Kong #Akeso #Ivonescimab #HARMONi-A

Akeso's Ivonescimab Achieves Fourth Breakthrough Therapy Designation for TNBC in China Akeso's innovative bispecific antibody, ivonescimab, has now received its fourth Breakthrough Therapy Designation in China for triple-negative breast cancer treatment.

Akeso's Ivonescimab Achieves Fourth Breakthrough Therapy Designation for TNBC in China #China #Hong_Kong #TNBC #Akeso #Ivonescimab

Revolutionary Dual-Positive Immunotherapy for EGFR+ NSCLC Shows Promise at SITC 2025 Akeso's innovative immunotherapy, Ivonescimab, showcases remarkable findings in EGFR+ NSCLC, bolstering treatment options at SITC 2025.

Revolutionary Dual-Positive Immunotherapy for EGFR+ NSCLC Shows Promise at SITC 2025 #Hong_Kong #Akeso #Ivonescimab #HARMONi-A

Breakthrough in Lung Cancer Treatment: Ivonescimab Shines with 11.14-Month Median Progression-Free Survival The HARMONi-6 trial reveals that Ivonescimab, when combined with chemotherapy, significantly improves progression-free survival in lung cancer patients, showcasing its clinical promise.

Breakthrough in Lung Cancer Treatment: Ivonescimab Shines with 11.14-Month Median Progression-Free Survival #China #Hong_Kong #Ivonescimab #Chemotherapy #HARMONi-6

Investors Alert: Pomerantz Law Firm Probes Summit Therapeutics for Potential Fraud Pomerantz LLP investigates claims for investors of Summit Therapeutics Inc. amid allegations of securities fraud affecting share prices.

Investors Alert: Pomerantz Law Firm Probes Summit Therapeutics for Potential Fraud #USA #New_York #Pomerantz_LLP #Ivonescimab #Summit_Therapeutics

Innovative Ivonescimab Study Accepted by The Lancet for ESMO 2025 Presentation The results from Akeso's Phase III study on ivonescimab have garnered acceptance in The Lancet, set for presentation at ESMO 2025, showcasing significant advances in NSCLC treatment.

Innovative Ivonescimab Study Accepted by The Lancet for ESMO 2025 Presentation #China #Hong_Kong #oncology #Akeso #Ivonescimab

🌟 #Yidafang (Ivonescimab): Dual Power in #NSCLC!
🎬 Watch how it boosts immunity & blocks tumor growth!
👇 Share your thoughts!

📩 info@dengyuemed.com
🔗 dengyuemed.com

#HongKongPharmaceuticaldistributor #Pharmaceuticaldistributorinchina
#Immunotherapy #Ivonescimab

🌟 #Yidafang (Ivonescimab):
Dual #PD-1 & #VEGF Target for #NSCLC! 🌟
💊 Boosts immunity,
blocks tumor growth,
improves survival.

🔗 Learn more: dengyuemed.com/product/ivon...

#HongKongDrugWholesaleDistributor #HongKongDengYueMedicine #Ivonescimab
#Immunotherapy #CancerTreatment

Akeso Inc. Presents Pioneering Ivonescimab and Cadonilimab Research at ESMO 2025 Congress Akeso Inc. is set to showcase groundbreaking results for ivonescimab and cadonilimab at the ESMO 2025 Congress, marking crucial advancements in cancer therapy.

Akeso Inc. Presents Pioneering Ivonescimab and Cadonilimab Research at ESMO 2025 Congress #Hong_Kong #Cadonilimab #Ivonescimab #Akeso_Inc.

Pomerantz Law Firm Launches Investigation Into Summit Therapeutics Investor Claims Pomerantz LLP is probing potential securities fraud cases related to Summit Therapeutics Inc., focusing on significant stock price declines following clinical trial results.

Pomerantz Law Firm Launches Investigation Into Summit Therapeutics Investor Claims #USA #New_York #Pomerantz_LLP #Ivonescimab #Summit_Therapeutics

Ivonescimab Plus Chemotherapy Offers Promising Global Outcomes in Cancer Trials Latest findings from the HARMONi clinical trial confirm that ivonescimab plus chemotherapy effectively enhances overall survival rates in patients globally.

Ivonescimab Plus Chemotherapy Offers Promising Global Outcomes in Cancer Trials #Hong_Kong #Ivonescimab #Chemotherapy #HARMONi_Trial

Akeso Completes Patient Enrollment in Phase III Trial for Ivonescimab in Biliary Tract Cancer Akeso has announced the completion of patient enrollment for a Phase III trial evaluating ivonescimab in advanced biliary tract cancer against PD-L1 therapy.

Akeso Completes Patient Enrollment in Phase III Trial for Ivonescimab in Biliary Tract Cancer #China #Hong_Kong #Akeso #Ivonescimab #biliary_tract_cancer

Akeso Reports Record Sales and Major Oncology Advances in 2025 Interim Results Akeso, Inc. has shared its 2025 interim results, revealing spectacular commercial sales growth and significant breakthroughs in oncology and autoimmune therapies.

Akeso Reports Record Sales and Major Oncology Advances in 2025 Interim Results #Akeso #Cadonilimab #Ivonescimab

Akeso Begins Phase III Trial of Ivonescimab for Limited-Stage SCLC Akeso, Inc. has announced the commencement of a Phase III trial for Ivonescimab, targeting limited-stage small cell lung cancer following radiotherapy, marking a significant advancement in treatment options.

Akeso Begins Phase III Trial of Ivonescimab for Limited-Stage SCLC #Hong_Kong #Akeso #Ivonescimab #SCLC

Akeso Completes First Dosing in Phase III Study of Ivonescimab for NSCLC Treatment Akeso, Inc. has completed the first dosing of patients in a pivotal Phase III clinical trial evaluating ivonescimab for Non-Small Cell Lung Cancer resistant to immunotherapy.

Akeso Completes First Dosing in Phase III Study of Ivonescimab for NSCLC Treatment #Hong_Kong #Akeso #Ivonescimab #NSCLC

NMPA Approves Ivonescimab for Advanced Lung Cancer Treatment: A New Hope The NMPA has approved Ivonescimab combined with chemotherapy for advanced squamous non-small cell lung cancer, marking a significant milestone in cancer treatment.

NMPA Approves Ivonescimab for Advanced Lung Cancer Treatment: A New Hope #China #Hong_Kong #Cancer_Treatment #Akeso #Ivonescimab

Akeso Initiates Phase III Clinical Trial for Ivonescimab in Pancreatic Cancer Treatment Akeso has announced the enrollment of the first patient in its Phase III trial for Ivonescimab, targeting pancreatic cancer with a new innovative approach.

Akeso Initiates Phase III Clinical Trial for Ivonescimab in Pancreatic Cancer Treatment #Hong_Kong #pancreatic_cancer #Akeso #Ivonescimab

Akeso's Phase III Clinical Trial of Ivonescimab Launched for Advanced Colorectal Cancer Treatment Akeso has initiated its Phase III trial (AK112-312/HARMONi-GI6) for ivonescimab in treating advanced metastatic colorectal cancer, targeting an urgent clinical need.

Akeso's Phase III Clinical Trial of Ivonescimab Launched for Advanced Colorectal Cancer Treatment #Hong_Kong #Akeso #Ivonescimab #Colorectal_Cancer